Immunovant, Inc. (IMVT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$28.39-5.05%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IMVT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including…
Stated in 2 of 2 supplied quarters. Management reported: “Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE) • Current cash balance provides runway to the potential launch of IMVT-1402 in GD • Roivant will host a live conference call and webcast at 8:00 a.m.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including…”
“Other clinical development timelines remain on track for IMVT-1402, including potentially registrational trials in GD, MG, CIDP, and SjD.”
Financial Highlights for Fiscal First Quarter Ended June 30, 2026: Cash Position: As of June 30, 2026, Immunovant’s cash and cash equivalents totaled $797.8 million, providing runway to the potential…
Stated in 2 of 2 supplied quarters. Management reported: “Financial Highlights for Fiscal First Quarter Ended June 30, 2026: Cash Position: As of June 30, 2026, Immunovant’s cash and cash equivalents totaled $797.8 million, providing runway to the potential commercial launch of IMVT-1402 in GD, based on our current operating plan.” “Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2026: Cash Position: As of March 31, 2026, Immunovant’s cash and cash equivalents totaled approximately $902.1 million, providing runway for announced indications through the potential commercial launch of IMVT-1402 in GD.”
“Financial Highlights for Fiscal First Quarter Ended June 30, 2026: Cash Position: As of June 30, 2026, Immunovant’s cash and cash equivalents totaled $797.8 million, providing runway to the potential…”
“Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2026: Cash Position: As of March 31, 2026, Immunovant’s cash and cash equivalents totaled approximately $902.1 million, providing runway…”
Research and Development Expenses: Research and development (R&D) expenses were $142.6 million for the three months ended June 30, 2026, compared to $101.2 million for the three months ended June 30,…
Stated in 2 of 2 supplied quarters. Management reported: “Research and Development Expenses: Research and development (R&D) expenses were $142.6 million for the three months ended June 30, 2026, compared to $101.2 million for the three months ended June 30, 2025.” “R&D Expenses: Research and development expenses were $142.3 million for the three months ended March 31, 2026, compared to $93.7 million for the three months ended March 31, 2025.”
“Research and Development Expenses: Research and development (R&D) expenses were $142.6 million for the three months ended June 30, 2026, compared to $101.2 million for the three months ended June 30,…”
“R&D Expenses: Research and development expenses were $142.3 million for the three months ended March 31, 2026, compared to $93.7 million for the three months ended March 31, 2025.”
Prepare for potential commercial launch of IMVT-1402 in Graves' disease based on current cash runway and clinical progress.
Cease development of batoclimab after Phase 3 failures to concentrate resources on IMVT-1402 clinical programs.
Over the trailing year it converted 0.84x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.